FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2020348444> ?p ?o ?g. }

• W2020348444 endingPage "315" @default.
• W2020348444 startingPage "309" @default.
• W2020348444 abstract "Recombinant interferon alpha-2b (rIFN-α2b) is an effective therapy for chronic-phase chronic myelogenous leukemia (CML). Polyethylene glycol-modified rIFN-α2b is a novel formulation with a serum half-life (∼40 h) compatible with once-weekly dosing. This open-label, noninferiority trial randomized 344 newly diagnosed CML patients: 171 received subcutaneous pegylated rIFN-α2b (6 μg/kg/week); 173 received rIFN-α2b (5 million International Units/m2/day). Primary efficacy end point was the 12-month major cytogenetic response (MCR) rate (<35% Philadelphia chromosome-positive cells). Modified efficacy analysis included all MCRs >12 months, except for patients discontinuing treatment after 6 months and achieving an MCR on other salvage therapy. The MCR rates were 23% for pegylated rIFN-α2b vs 28% for rIFN-α2b in the primary efficacy analysis and 26 vs 28% in the prospectively modified efficacy analysis. However, a significant imbalance in baseline hematocrit (HCT), a significant predictor of cytogenetic response (P=0.0001), was discovered: 51 (30%) patients treated with pegylated rIFN-α2b had low HCT (<33%) vs 33 (19%) rIFN-α2b-treated patients. Among patients with HCT >33%, the MCR rate was 33 vs 31%. The adverse event profile of weekly pegylated rIFN-α2b was comparable to daily rIFN-α2b. Once-weekly pegylated rIFN-α2b is an active agent for the treatment of newly diagnosed CML with an efficacy and safety profile similar to daily rIFN-α2b, although statistical noninferiority was not demonstrated." @default.
• W2020348444 created "2016-06-24" @default.
• W2020348444 creator A5004577239 @default.
• W2020348444 creator A5011326274 @default.
• W2020348444 creator A5036980753 @default.
• W2020348444 creator A5040941721 @default.
• W2020348444 creator A5055166871 @default.
• W2020348444 creator A5072027146 @default.
• W2020348444 creator A5074486986 @default.
• W2020348444 date "2003-12-04" @default.
• W2020348444 modified "2023-10-16" @default.
• W2020348444 title "Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study" @default.
• W2020348444 cites W1498708301 @default.
• W2020348444 cites W1828405036 @default.
• W2020348444 cites W188630774 @default.
• W2020348444 cites W1928548710 @default.
• W2020348444 cites W1985269587 @default.
• W2020348444 cites W2011474502 @default.
• W2020348444 cites W2019465287 @default.
• W2020348444 cites W2038990138 @default.
• W2020348444 cites W2058190985 @default.
• W2020348444 cites W2117806883 @default.
• W2020348444 cites W2142337801 @default.
• W2020348444 cites W2142969636 @default.
• W2020348444 cites W236820854 @default.
• W2020348444 cites W2465903784 @default.
• W2020348444 cites W38386901 @default.
• W2020348444 cites W4247887669 @default.
• W2020348444 cites W4293241248 @default.
• W2020348444 cites W977069352 @default.
• W2020348444 doi "https://doi.org/10.1038/sj.leu.2403217" @default.
• W2020348444 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14671645" @default.
• W2020348444 hasPublicationYear "2003" @default.
• W2020348444 type Work @default.
• W2020348444 sameAs 2020348444 @default.
• W2020348444 citedByCount "67" @default.
• W2020348444 countsByYear W20203484442012 @default.
• W2020348444 countsByYear W20203484442013 @default.
• W2020348444 countsByYear W20203484442014 @default.
• W2020348444 countsByYear W20203484442015 @default.
• W2020348444 countsByYear W20203484442016 @default.
• W2020348444 countsByYear W20203484442017 @default.
• W2020348444 countsByYear W20203484442018 @default.
• W2020348444 countsByYear W20203484442019 @default.
• W2020348444 countsByYear W20203484442020 @default.
• W2020348444 countsByYear W20203484442021 @default.
• W2020348444 countsByYear W20203484442022 @default.
• W2020348444 crossrefType "journal-article" @default.
• W2020348444 hasAuthorship W2020348444A5004577239 @default.
• W2020348444 hasAuthorship W2020348444A5011326274 @default.
• W2020348444 hasAuthorship W2020348444A5036980753 @default.
• W2020348444 hasAuthorship W2020348444A5040941721 @default.
• W2020348444 hasAuthorship W2020348444A5055166871 @default.
• W2020348444 hasAuthorship W2020348444A5072027146 @default.
• W2020348444 hasAuthorship W2020348444A5074486986 @default.
• W2020348444 hasBestOaLocation W20203484441 @default.
• W2020348444 hasConcept C126322002 @default.
• W2020348444 hasConcept C141071460 @default.
• W2020348444 hasConcept C197934379 @default.
• W2020348444 hasConcept C203014093 @default.
• W2020348444 hasConcept C203092338 @default.
• W2020348444 hasConcept C2522874641 @default.
• W2020348444 hasConcept C2776178377 @default.
• W2020348444 hasConcept C2776408679 @default.
• W2020348444 hasConcept C2776461080 @default.
• W2020348444 hasConcept C2776960273 @default.
• W2020348444 hasConcept C2777288759 @default.
• W2020348444 hasConcept C2778461978 @default.
• W2020348444 hasConcept C2780040827 @default.
• W2020348444 hasConcept C2909179924 @default.
• W2020348444 hasConcept C31760486 @default.
• W2020348444 hasConcept C535046627 @default.
• W2020348444 hasConcept C71924100 @default.
• W2020348444 hasConcept C90924648 @default.
• W2020348444 hasConceptScore W2020348444C126322002 @default.
• W2020348444 hasConceptScore W2020348444C141071460 @default.
• W2020348444 hasConceptScore W2020348444C197934379 @default.
• W2020348444 hasConceptScore W2020348444C203014093 @default.
• W2020348444 hasConceptScore W2020348444C203092338 @default.
• W2020348444 hasConceptScore W2020348444C2522874641 @default.
• W2020348444 hasConceptScore W2020348444C2776178377 @default.
• W2020348444 hasConceptScore W2020348444C2776408679 @default.
• W2020348444 hasConceptScore W2020348444C2776461080 @default.
• W2020348444 hasConceptScore W2020348444C2776960273 @default.
• W2020348444 hasConceptScore W2020348444C2777288759 @default.
• W2020348444 hasConceptScore W2020348444C2778461978 @default.
• W2020348444 hasConceptScore W2020348444C2780040827 @default.
• W2020348444 hasConceptScore W2020348444C2909179924 @default.
• W2020348444 hasConceptScore W2020348444C31760486 @default.
• W2020348444 hasConceptScore W2020348444C535046627 @default.
• W2020348444 hasConceptScore W2020348444C71924100 @default.
• W2020348444 hasConceptScore W2020348444C90924648 @default.
• W2020348444 hasIssue "2" @default.
• W2020348444 hasLocation W20203484441 @default.
• W2020348444 hasLocation W20203484442 @default.
• W2020348444 hasOpenAccess W2020348444 @default.
• W2020348444 hasPrimaryLocation W20203484441 @default.
• W2020348444 hasRelatedWork W160090104 @default.

• next